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Abstract
Background: Immune activation is a strong predictor of disease progression in HIV infection. Combinatorial plasma
biomarker signatures that represent surrogate markers of immune activation in both viremic and aviremic HIV patients on
combination antiretroviral therapy (cART) have not been defined. Here, we identify a plasma inflammatory biomarker
signature that distinguishes between both viremic and aviremic HIV patients on cART and healthy controls and examine
relationships of this signature to markers of disease progression.
Methods: Multiplex profiling and ELISA were used to detect 15 cytokines/chemokines, soluble IL-2R (sIL-2R), and soluble
CD14 (sCD14) in plasma from 57 HIV patients with CD4 nadir ,300 cells/ml and 29 healthy controls. Supervised and
unsupervised analyses were used to identify biomarkers explaining variance between groups defined by HIV status or drug
abuse. Relationships between biomarkers and disease markers were examined by Spearman correlation.
Results: The majority (91%) of HIV subjects were on cART, with 38% having undetectable viral loads (VL). Hierarchical
clustering identified a biomarker cluster in plasma consisting of two interferon-stimulated gene products (CXCL9 and
CXCL10), T cell activation marker (sIL-2R), and monocyte activation marker (sCD14) that distinguished both viremic and
aviremic HIV patients on cART from controls (p,0.0001) and were top-ranked in variables important in projection plots. IL-
12 and CCL4 were also elevated in viremic and aviremic patients compared to controls (p,0.05). IL-12 correlated with IFNa,
IFNc, CXCL9, and sIL-2R (p,0.05). CXCL10 correlated positively with plasma VL and percentage of CD16+ monocytes, and
inversely with CD4 count (p=0.001, ,0.0001, and 0.04, respectively).
Conclusion: A plasma inflammatory biomarker signature consisting of CXCL9, CXCL10, sIL-2R, and sCD14 may be useful as a
surrogate marker to monitor immune activation in both viremic and aviremic HIV patients on cART during disease
progression and therapeutic responses.
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Introduction
Chronic immune activation is a hallmark of HIV disease that is
strongly linked to disease progression [1,2]. Markers of immune
activation in both treated and untreated HIV-infected patients
include enhanced expression of activation markers on peripheral
blood T cells, B cells, monocytes, dendritic cells, and natural killer
(NK) cells, and increased levels of inflammatory cytokines and
chemokines [1,3,4,5,6,7]. The causes of immune activation in HIV
infection are poorly understood, but are likely to be multifactorial
and include persistent elevation of type I and II interferons (IFN),
innate and adaptive immune responses to HIV infection and
bacterial products that translocate from a leaky gut, direct effects
of HIV virions and/or viral proteins, co-infections with non-HIV
pathogens, non-antigen specific bystander activation of immune
cells, and dysregulated cytokine and chemokine production
[1,3,4,8,9]. The innate immune system responds immediately
during the course of HIV infection through production of type I
and II IFN and other cytokines, and viral replication correlates
with upregulation of type I IFN-stimulated genes. Type 1
interferons, produced primarily by plasmacytoid dendritic cells
(pDC), along with activated monocytes and T cells, play a central
role in mediating persistent inflammation in HIV infection
[3,10,11,12]. Despite extensive study, the mechanisms driving
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chronic inflammation are poorly understood.
Despite years of suppressive combined antiretroviral therapy
(cART) in patients with undetectable plasma viral loads (VL) and
CD4 reconstitution to normal or near normal levels, low levels of
immune activation persist in treated HIV infection. Elevated
circulating levels of activated immune cells [13,14,15,16,17],
soluble activation markers (e.g., sTNFR, sCD27, sCD40L, sCD14,
type I/II IFN, CCL2, CCL4, C-reactive protein, and D-dimer)
[7,18,19,20,21,22,23,24,25], and markers of microbial transloca-
tion [9,26] have been used to study relationships between immune
activation and clinical outcomes in patients on cART. A number
of studies have focused on identifying biomarkers to monitor HIV
immunopathogenesis in patients on cART, yet no single marker or
combinatorial biomarker signature has proved to be reliable for
diagnostic or therapeutic purposes. An inflammatory biomarker
signature that can distinguish a broad spectrum of HIV patients
with suppressed or nonsuppressed VL on cART from uninfected
healthy controls may be useful as a surrogate marker to monitor
chronic immune activation during disease progression and
therapeutic responses.
In this study, we performed multiplex cytokine/chemokine
profiling and used supervised and unsupervised classification
methods to identify a plasma inflammatory biomarker signature
that representsa potentialsurrogate markerofimmuneactivation in
both viremic and aviremic HIV patients on cART. Because the
cohort had a high frequency of drug abuse, we also evaluated the
effects of active cocaine use on biomarker expression. We identified
a plasma biomarker signature consisting of 2 interferon-stimulated
gene products (CXCL9 and CXCL10), T cell activation marker
(sIL-2R), and monocyte activation marker (sCD14) that distin-
guishes viremic and aviremic HIV patients on cART from
uninfected healthy controls. This biomarker signature may serve
as a surrogate marker of immune activation that may prove useful
for monitoring disease progression and therapeutic responses in
HIV patients on cART with diverse clinical phenotypes.
Methods
Ethics statement
All HIV+ subjects were enrolled with written informed consent
and IRB approval at each study site (Lemuel Shattuck Hospital,
Manhattan HIV Brain Bank, National Neurological AIDS Bank,
California NeuroAIDS Tissue Network, Texas NeuroAIDS
Research Center). The IRB at Dana-Farber Cancer Institute
approved the research involving HIV+ subjects as exempt because
samples and clinical data were provided without any patient or
donor identifiers. HIV/HCV-negative control plasma samples
from healthy control subjects were purchased from Bioreclamation
LLC or Research Blood Components (Brighton, MA), or were
collected from HIV-negative healthy volunteers at Dana-Farber
Cancer Institute with written informed consent and IRB approval
from Dana-Farber Cancer Institute.
Subjects
HIV+ subjects (n=57) with CD4 nadir ,300 cells/ml and
relatively low CD4 counts (median 81, range 3–688 cells/ml) were
recruited at the Lemuel Shattuck Hospital (n=26), and at four
sites (Manhattan HIV Brain Bank, National Neurological AIDS
Bank, California NeuroAIDS Tissue Network, Texas NeuroAIDS
Research Center) in the National NeuroAIDS Tissue Consortium
(NNTC; n=26) or CNS HIV Anti-Retroviral Therapy Effects
Research (CHARTER; n=5). The majority (91%) were on
cART. Plasma HIV RNA levels were log10 transformed for
statistical analysis. Undetectable plasma VL values were assigned a
log10 value of 2.6 (400 HIV RNA copies/ml), reflecting the
sensitivity cutoff of the assay most widely used during these
assessments; values below this cutoff reflect lower assay sensitivity
(25 or 50 copies) for some sites. Current substance abuse (within 30
days of plasma sampling) was determined by the Psychiatric
Research Interview for Substance and Mental Disorders (PRISM)
[27] or Composite International Diagnostic Interview (CIDI) [28]
and urine toxicology at time of blood draw. HIV/HCV-negative
control plasma samples from healthy control subjects (n=29) were
purchased from Bioreclamation LLC (n=13) or Research Blood
Components (Brighton, MA; n=2), or were collected from normal
HIV-negative healthy volunteers at Dana-Farber Cancer Institute
(n=14).
Cytokine/chemokine profiling by multiplex assay
A multiplex immunoassay (Bio-source 25-plex Human Cytokine
Assay; Invitrogen) was used according to the manufacturer’s
instructions to measure levels of IL-1RA, IL-1b, IL-2, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, IFN-a, IFNc,
TNF, sIL-2R, GM-CSF, CCL2/MCP-1, CCL3/MIP-1a, CCL4/
MIP-1b, CXCL10/IP-10, CXCL9/MIG, CCL11/eotaxin, and
CCL5/RANTES. Briefly, plasma samples were diluted 1:2 with
assay buffer, and incubated with antibody-coupled beads.
Complexes were washed, incubated with biotinylated detection
antibody, and subsequently with streptavidin-phycoerythrin, prior
to assessing titers of cytokine concentration. Standard curves run
in duplicate were established with recombinant cytokines. Analyte
levels were determined using a multiplex array reader from
Luminex
TM Instrumentation System (Bio-Plex Workstation from
Bio-Rad); plasma samples were run in duplicate and analyte
concentrations were calculated as the average of two independent
measures using Bioplex Manager Software.
Quantification of soluble CD14 using ELISA
Levels of soluble CD14 in plasma samples were measured using
a commercial assay (Quantikine ELISA kit, R & D systems).
Flow cytometry analysis of monocyte subsets
PBMC were isolated from fresh peripheral blood samples from
20 HIV+ subjects from the Lemuel Shattuck Hospital by Ficoll-
Paque centrifugation and monocyte subsets analyzed by FACS
analysis as described [29]. Fluorochrome-conjugated Abs used for
FACS analysis were CD14, CD16, CD19, CD33, CD16b,
CD66b, CD56, and CD3 (Beckman Coulter); CD4, CCR5,
CD69, and HLA-DR (BD Pharmingen). To quantify CD16+
monocytes, PBMC depleted of CD3
+ T-cells were stained with
PE-CD14 and PE-Cy5 CD16 Abs and FITC-conjugated Abs
against T-cell (CD3), granulocyte (CD16b/CD66b), B cell (CD19),
NK cell (CD56), and dendritic cell (CD1c) markers. CD16+
monocytes (CD14+/CD16+) were distinguished from granulocytes
by HLA-DR and lack of CD16b/CD66b expression, and from
NK cells by higher forward and side scatter characteristics, CD14,
CD4, and CD33, and lack of CD56 expression
Data processing, normalization, and analysis
Raw values for each analyte were normalized to the mean of
healthy controls, log2-transformed, and then subjected to super-
vised or unsupervised hierarchical clustering. The raw data,
normalized values, and clinical data for each sample are included
as supplemental data (Table S1). Cytokines with .20% missing
data were excluded from further analysis; hence, analysis was
performed for 16 biomarkers represented in the 25-plex assay in
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detection (LOD) for each biomarker was specified by the
manufacturer for each lot number. For imputation of missing
(non-detected) values, the LOD was used to replace missing values.
For one analyte (IL-15), missing values were imputed in lowest-
value mode as described [30] using the lowest detected value
(LDV), corresponding to the most frequently occurring value
(mode) among detectable values below the LOD. In this instance,
missing values were replaced using the LDV rather than the LOD
because the LDV was observed for a significant percentage of
samples (15%) and the coefficient of variance for these
observations (9.7%) indicated the measurement was reproducible.
We chose this approach for imputation because it is conservative,
reducing the probability of artificially creating differential
expression or correlations. Hierarchical clustering was performed
with dChip software using Euclidean distance and average linkage
to analyze plasma biomarker levels across HIV subjects and
healthy controls. Comparison criteria required the fold change
(FC) between group means to exceed a specific threshold (FC$1.3)
and mean difference to be statistically significant by unpaired t-test
(p,0.05 with false discovery rate (FDR) controlled at ,5%).
Principal component analysis (PCA) and partial-least squares
discriminant analysis (PLS-DA) were performed on the Metaboa-
nalyst web portal [31] using normalized and autoscaled expression
values. The web portal utilizes the prcomp function of the stats
package, and plsr function of the pls package of R, respectively.
Class labels were permuted 2000 times to test whether differences
between groups are significant. For every PLS-DA model built, the
sum of squares between/sum of squares within (i.e., the B/W ratio)
was computed and displayed in a histogram of random class
assignments [32]. To examine relationships between normalized
cytokine expression values and clinical covariates, Spearman
correlations were run using the correlation test function in the stats
package of R version 2.10.1 (http://www.r-project.org/).
Results
Plasma biomarker cluster consisting of CXCL9, CXCL10,
sIL-2R, and sCD14 distinguishes HIV subjects from
controls
The study cohort consisted of 57 HIV subjects with advanced
disease (CD4 nadir ,300; median, 61 cells/ml; range, 1–261 cells/
ml), relatively low CD4 counts (median, 81 cells/ml; range, 3 – 688
cells/ml), variable plasma HIV RNA levels (median 2,460 copies/
ml; range, undetectable – 2,210,000 copies/ml), and high frequency
of recent substance abuse (70%) and HCV co-infection (47%)
(Table 1). The majority were on cART (91%), with 38% having
undetectable plasmaVL (,400 HIV RNA copies/ml). HIV/HCV-
negative subjects were used as healthy controls (n=29).
To identify an inflammatory biomarker profile that best
distinguishes HIV patients from uninfected healthy controls, we
analyzed expression levels of 17 biomarkers across all HIV-
infected subjects and healthy controls by univariate analysis and
semi-supervised hierarchical clustering. Levels of 7 inflammatory
biomarkers (CXCL9, CXCL10, sIL-2R, CCL4, sCD14, IL-6, and
CCL2) were higher in HIV+ subjects compared to healthy control
subjects (FC$1.3, p,0.05, FDR 0) (Table 2). Two chemokines
(CXCL9, CXCL10), the T cell activation marker soluble IL-2
receptor (sIL-2R), and monocyte activation marker sCD14 were
the top-ranked biomarkers based on p-values (FC 1.46 – 3.71,
p,0.0001) that distinguished HIV subjects from controls.
Additional biomarkers elevated in HIV subjects compared to
controls were CCL4, IL-6, IL-12, and CCL2 (FC 1.19 - 1.61,
p,0.05) (Table 2). Hierarchical clustering identified a biomarker
cluster consisting of increased CXCL9, CXCL10, sIL-2R, and
sCD14 that distinguished HIV-infected subjects from healthy
controls (Figure 1). Two additional biomarker clusters consisted of
CCL2 and IFNc, and IL-12, IL-1RA, and CCL4, but neither
distinguished HIV from control subjects (Figure 1). Thus, CXCL9,
CXCL10, sIL-2R, and sCD14 represent a plasma biomarker
cluster that distinguishes HIV subjects from healthy controls.
Plasma CXCL9, CXCL10, sIL-2R, and sCD14 levels
distinguish both viremic and aviremic HIV subjects on
cART from controls
To determine whether increased CXCL9, CXCL10, sIL-2R,
and sCD14 levels can distinguish HIV patients on cART from
Table 1. Demographic and clinical characteristics of HIV+
subjects in the study cohort.
Age (years)
Mean 6 SD 4567.3
Median (range) 44 (32–63)
Gender
Male 43 (75%)
Female 14 (25%)
Race
African American 25 (44%)
Caucasian 15 (26%)
Hispanic 14 (25%)
Other 3 (5%)
Risk factor
Sexual transmission 17 (30%)
Intravenous drug abuse 40 (70%)
CD4 T cell count (cells/ml)
Mean 6 SD 1226126
Median (range) 81 (3–688)
CD4 nadir T cell count (cells/ml)
Mean 6 SD 82669.1
Median (range) 61 (1–261)
Plasma HIV RNA (copies/ml)
Mean 6 SD 131,3656408,505
Median (range) 2460 (,50–2,210,000)
,400 copies/ml 22 (38%)
cART
Yes 52 (91%)
No 5 (9%)
HCV co-infection
Positive 27 (47%)
Negative 18 (32%)
Unknown 12 (21%)
Substance abuse
Opiates* 22 (38%)
Cocaine* 32 (55%)
None 17 (30%)
(n=57).
*14 subjects used both opiate and cocaine based on self-report or urine toxicology
at time of plasma sampling.
doi:10.1371/journal.pone.0030881.t001
Plasma Biomarker Signature of Immune Activation
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e30881uninfected controls regardless of the level of viral control in
plasma, we performed univariate analysis and hierarchical
clustering across subjects segregated according to either detectable
(.400 HIV RNA copies/ml) or undetectable (,400 copies/ml)
plasma VL. The viremic and aviremic groups had similar median
age and nadir CD4 counts, but median current CD4 counts were
lower in viremic compared to aviremic subjects (50 versus 152
cells/ml, p,0.001). The four biomarkers (CXCL9, CXCL10, sIL-
2R, and sCD14) identified in the preceding analysis were
significantly increased in both the viremic and aviremic groups
(FC 1.5–4.7 and 1.4–3.1, respectively, p,0.001) compared to
healthy controls, distinguishing both groups from healthy controls
in supervised analyses (Table 2 and Figure 2). By univariate
analysis, we also identified additional plasma biomarkers increased
in viremic (CCL2, CCL4, and IL-6) or aviremic (IL-12 and CCL4)
subjects compared to controls (FC$1.3, p,0.05, FDR 0%)
(Table 2) and found higher IL-12 levels in aviremic (FC 1.36,
p=0.003) but not viremic (FC 1.11, p=0.138) subjects compared
to controls. CXCL9, CXCL10, sIL-2R, and sCD14 levels were
slightly higher in viremic than in aviremic subjects, and IL-12
levels were slightly higher in aviremic than in viremic subjects
(Table 2). These differences in cytokine/chemokine levels between
the viremic and aviremic groups were less than expected, probably
reflecting the selection of subjects at late stages of disease.
Unsupervised hierarchical clustering based on CXCL9, CXCL10,
sIL-2R, and sCD14 levels across viremic, aviremic, and control
subjects yielded low rate of misclassification corresponding to 20%
(7/35) of viremic (Figure S1, panel A) and 18% (4/22) of aviremic
subjects (Figure S1, panel B). The accuracy of unsupervised
clustering for correctly predicting classification of HIV versus
control subjects was not improved by adding any other biomarker,
alone or in combination, to the analysis. Thus, CXCL9, CXCL10,
sIL-2R, and sCD14 represent a combinatorial inflammatory
biomarker panel that distinguishes both viremic and aviremic
HIV patients on cART from healthy controls with ,80%
accuracy, and its predictive accuracy for classifying patients by
unsupervised clustering is not improved by adding additional
cytokine/chemokine biomarkers.
Plasma CXCL9, CXCL10, sIL-2R, and sCD14 explain most
of the variance between all HIV or aviremic HIV subjects
and controls
To add another layer of dimensionality to analysis of the data
set, we performed PCA (unsupervised analysis) and PLS-DA
Figure 1. Plasma CXCL9, CXCL10, sIL-2R, and sCD14 represent a biomarker cluster that distinguishes HIV subjects from healthy
uninfected controls. (A) Hierarchical clustering (supervised only by sample) by Euclidean distance and average linkage of 17 plasma biomarkers in
57 HIV patients and 29 healthy uninfected controls shows increased plasma levels and clustering of CXCL9, CXCL10, sIL-2R, and sCD14 (highlighted in
box) in HIV subjects compared to healthy controls. In heat maps, red and blue represent increased and decreased levels relative to the mean level of a
biomarker, respectively. Each column and row defines individual patient and biomarkers, respectively.
doi:10.1371/journal.pone.0030881.g001
Table 2. Plasma biomarkers that distinguish all HIV subjects, viremic HIV subjects, and aviremic HIV subjects, from healthy
controls.
Cytokines/Chemokines
HIV subjects versus controls
(n=57)
Viremic subjects versus controls
(n=35) Aviremic subjects versus controls (n=22)
FC p value FC p value FC p value
CXCL9 3.71 ,0.0001 4.69 ,0.0001 3.07 ,0.0001
CXCL10 3.25 ,0.0001 4.26 ,0.0001 2.03 ,0.0001
sIL-2R 2.22 ,0.0001 2.38 ,0.0001 2.25 ,0.001
CCL4 1.61 0.0267
* 1.67 0.0188
* 1.91 0.0441
*
sCD14 1.46 ,0.0001 1.53 ,0.0001 1.40 ,0.0001
IL-6 1.35 0.0143
* 1.45 0.0081
* 1.27 0.1861
CCL2 1.35 0.0475
* 1.45 0.0179
* 1.36 0.2110
IL-12 1.19 0.0071
* 1.11 0.1380 1.36 0.0037
*
Shown are the 8 analytes that demonstrated significant differences in at least one inter-group comparison using the following criteria: mean fold change (FC)$1.3, and
p,0.05 by unpaired t-test;
*difference is statistically significant (p,0.05); Comparisons with bold fonts are top ranked biomarkers (p,0.0001 and p,0.001).
doi:10.1371/journal.pone.0030881.t002
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the data by reducing the number of dimensions, thereby revealing
internal structure of the data. First, we performed PCA, which finds
thedirections ofmaximumvarianceina dataset withoutreferringto
class labels. PCA applied to 17 plasma biomarkers revealed that the
first 3 components explain 50.7% of the variance between HIV
subjects and controls along the axis defined by PC1, PC2, and PC3,
with CXCL9, CXCL10, sIL-2R, and sCD14 clustering together in
loading plots (data not shown). However, PCA did not accurately
segregate all HIV or aviremic HIV subjects from controls.
Next, we analyzed the data using PLS-DA, a supervised
classification method based on the partial least squares (PLS)
approach that uses multiple linear regression analysis to find the
direction of maximum covariance between a dataset and class
membership and prioritize features that contribute significantly to
class prediction. A permutation test (2000 permutations) was then
applied to determine the importance of class separation in the
dataset. When PLS-DA was applied to 17 plasma biomarkers and
data from all 57 HIV subjects were projected onto these 3
components, HIV and control subjects could be separated along
the axis defined by 3 components explaining 46.5% of the
variance (Figure 3A). Permutation tests showed significant
separation distance between the 2 groups (p,0.0005). Similar
analysis applied to the aviremic group showed that aviremic HIV
subjects and controls could be separated along the axis defined by
3 components explaining 48.3% of the variance in the matrix of 17
plasma biomarkers (Figure 3B). Permutation tests confirmed
significant separation between the 2 groups (p,0.0005). Features
that contribute significantly to class prediction were then ranked
using variables important in projection (VIP) scores, which are
based on the weighted coefficients of the PLS model; VIP scores
above a threshold of 1 are considered important. VIP score plots
revealed sCD14, CXCL10, CXCL9, and sIL-2R as the top 4
biomarkers explaining the class separation between all HIV or
aviremic HIV subjects and controls (Figure 3). These results
provide additional evidence that CXCL9, CXCL10, sIL-2R, and
sCD14 represent a combinatorial plasma inflammatory biomarker
signature that distinguishes both viremic and aviremic HIV
patients on cART from uninfected controls.
Relationship of biomarkers in the combinatorial
signature to interferons and HIV disease markers
To examine relationships between individual components of the
four-marker signature identified in the studies described above and
interferons or other biomarkers in HIV subjects (n=57), we
performed Spearman correlation analysis. We found the following
correlations: 1) plasma sCD14 correlated with IL-6 (p=0.003) and
IL-15 (p=0.004), and trended towards significance with CCL3
(p=0.058) (Figure 4A); 2) CXCL9 correlated with CXCL10 and
IL-12 (p=0.002 and p=0.006, respectively) (Figure 4B); 3) sIL-2R
correlated with CXCL10 and IL-12 (p=0.041 and p=0.042
respectively, Figure 4B and C). We examined the relationship of
type I/II IFN levels to other biomarkers and found that IFNa and
c correlated with IL-12 (p=0.002 and p=0.001, respectively;
Figure 4C). IFNa also correlated with CCL4 and CCL2 (r=0.400,
p=0.002 and r=0.291, p=0.027, respectively, data not shown).
These findings imply a close relationship between type I and II
IFNs, IL-12, and individual components of the inflammatory
biomarker signature.
We then examined the relationship between individual
biomarkers within the combinatorial biomarker signature and
HIV disease markers (CD4 count, plasma VL, and LPS). This
analysis revealed that only CXCL10 showed significant correla-
tions with disease markers, in particular an inverse correlation with
CD4 count and positive correlation with plasma VL (r=20.271,
p=0.041 and r=0.406, p=0.001, respectively) (Fig. 5). Because
previous studies demonstrated an association between expansion
of the proinflammatory CD16+ monocyte subset and HIV disease
progression [29,33,34,35,36], we also examined the relationship
between signature biomarkers and frequency of the CD16+
monocyte subset using data for 20 HIV-infected subjects available
from our previous study [29]. We found a positive correlation
between CXCL10 levels and frequency (%) of CD16+ monocytes
(p,0.0001, Figure 5, right panel). These findings identify
CXCL10 as a component of the plasma inflammatory biomarker
signature we identified in HIV subjects that is strongly associated
with disease markers (high plasma VL and low CD4 count) and
increased frequency of CD16+ monocytes.
To further examine inter-relationships between biomarkers as
well as relationships between biomarkers and HIV disease markers
(CD4 count and plasma VL), we performed similar analyses for
viremic and aviremic HIV subjects. In viremic subjects, sCD14
correlated with IFNc and IL-15 (r=0.41, p=0.014 and r=0.403,
p=0.016, respectively), while CXCL9 correlated with IL-12 and
CXCL10 (r=0.357, p=0.034; r=0.468, p=0.004, respectively)
and IL-12 correlated with IFNa and IFNc (r=0.435, p=0.008
and r=0.544, p=0.0007, respectively). In aviremic subjects,
sCD14 levels correlated with IL-6 (r=0.530, p=0.012), while
Figure 2. Increased plasma levels of CXCL9, CXCL10, sIL-2R, and sCD14 distinguish viremic and aviremic HIV subjects from
controls. Supervised hierarchical clustering of plasma CXCL9, CXCL10, sIL-2R, and sCD14 levels measured in viremic (panel A) or aviremic, (panel B)
HIV subjects compared to healthy controls. In heat maps, red and blue represent increased and decreased levels relative to the mean level of a
biomarker, respectively. Each column and row defines individual patient and biomarkers, respectively.
doi:10.1371/journal.pone.0030881.g002
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and r=0.572, p=0.005, respectively) and IFNa correlated with
CCL4 and CCL2 (r=0.540, p=0.009 and r=0.648, p=0.001,
respectively). However, none of the individual biomarker compo-
nents of the four-marker signature was associated with HIV
disease markers in either group. In particular, correlations
between CXCL10 and disease markers found in the studies
describe above for the total cohort of 57 HIV subjects (Fig. 5) were
lost when similar analyses were performed for the viremic and
aviremic subgroups. This difference may reflect insufficient
statistical power for this analysis given the smaller sample sizes
of these subgroups (n=35 and 22, respectively). These findings
demonstrate a close relationship between type I and II interferons,
IL-12, and monocyte-derived inflammatory cytokines/chemokines
in both viremic and aviremic HIV subjects on cART.
Cocaine abuse in HIV-infected subjects is associated with
biomarkers indicative of increased T cell activation
To explore relationships between plasma biomarker levels and
clinical subgroups, we analyzed biomarker levels in subjects
grouped according to presence or absence of a HIV-associated
neurocognitive disorders (HAND) clinical diagnosis, HCV co-
infection, and active use of cocaine or heroin. Unsupervised
hierarchical clustering identified a large cluster of subjects with
active cocaine abuse (primarily via intravenous route), represent-
ing 12/17 cocaine users with higher levels of sIL-2R, sCD14,
Figure 3. PLS-DA of 17 biomarkers shows separation of HIV subjects and aviremics from controls and identifies top-ranked
biomarkers accounting for separation between groups. (A) PLS-DA represented as a three dimensional scatter plot shows the top 3
components in the matrix of biomarker data (n=17 biomarkers) measured in HIV (green dots, n=57) and uninfected control subjects (red dots,
n=29). 46.5% of the variance observed in the matrix of biomarker data is explained by the first 3 components. Plot on the right shows variables
important in projection (VIP) plot ranking sCD14, CXCL9, CXCL10, and sIL-2R as the top 4 biomarkers accounting for the variance between all HIV
subjects and controls. (B) PLS-DA represented as a three dimensional scatter plot showing the top 3 components in the matrix of biomarker levels
measured in aviremic HIV subjects (red dots, n=22) and uninfected control samples (green dots, n=29). 48.3% of the variance in the matrix of
biomarkers is explained by the first 3 components. Plot on the right represents VIP plot ranking sCD14, CXCL9, CXCL10, and sIL-2R as the top 4
biomarkers explaining the variance between aviremic HIV subjects and uninfected controls.
doi:10.1371/journal.pone.0030881.g003
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(p=0.0005; data not shown), while no significant clustering was
associated with HAND or HCV co-infection. Therefore, we next
examined whether any unique plasma biomarker expression
pattern is associated with cocaine abuse defined by self report on
PRISM or CIDI interviews together with positive urine toxicology.
Comparing biomarker levels between these two groups using
dChip software revealed that sIL-2R was increased, while IL-17
was decreased (FC 2.6 and p=0.012 and FC 21.5 and p=0.046,
respectively; FDR 0.0) in viremic subjects with active cocaine use
and positive urine toxicology at time of plasma sampling versus
non-users with no self-reported cocaine/opiate usage and negative
Figure 4. Inter-relationships between plasma inflammatory biomarkers and interferons in HIV subjects on cART. (A) Plasma sCD14
shows positive correlation with IL-6, IL-15, and trend towards significant correlation with CCL3. (B) CXCL10 correlated positively with CXCL9 andsIL-2R,
while IL-12 was significantly associated with CXCL9. (C) IL-12 correlated positively with IFNa, IFNc, and sIL-2R. Shown are log2 transformed values of
measurements normalized to the mean of healthy controls. Data was analyzed by Spearman correlation, with p,0.05 considered significant.
doi:10.1371/journal.pone.0030881.g004
Figure 5. Relationships between plasma CXCL10 levels and CD4 count, plasma viral load, and frequency of CD16+ monocytes.
Plasma CXCL10 levels show positive correlation with plasma viral load and frequency of CD16+ monocytes, and negative correlation with CD4 counts.
Data was analyzed by Spearman correlation, with p,0.05 considered significant.
doi:10.1371/journal.pone.0030881.g005
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Furthermore, PLS-DA identified sIL-2R and IL-17 as top-ranked
biomarkers accounting for the separation between these two
groups based on VIP scores (Figure S2). These two groups had
similar median age, current and nadir CD4 counts, and mean
plasma VL. Together, these findings suggest that active cocaine
abuse is associated with markers indicative of T cell activation
(higher sIL-2R), and possibly depletion of the Th17 cells (lower IL-
17), in HIV-infected patients on nonsuppressive cART.
Discussion
By multiplex profiling, we identified a combinatorial inflamma-
tory biomarker signature in plasma consisting of 2 interferon-
stimulated gene products (CXCL9, CXCL10), T cell activation
marker (sIL-2R), and monocyte activation marker (sCD14) that
distinguishes viremic and aviremic HIV patients on cART from
uninfected controls. Increased CXCL10 correlated with low CD4
count and high plasma VL, consistent with previous studies in
other HIV cohorts [37,38]. We also found a positive correlation
between CXCL10 and frequency of the proinflammatory CD16+
monocyte subset, a subset that expands during HIV disease
progression. CXCL9, CXCL10, sIL-2R, and sCD14 were top-
ranked biomarkers explaining most of the variance between all
HIV subjects, or aviremic HIV subjects, and uninfected controls.
Thus, CXCL9, CXCL10, sIL-2R, and sCD14 represents a plasma
inflammatory biomarker signature that may be useful as a
surrogate marker to monitor interferon responses and chronic
immune activation in both viremic and aviremic HIV patients on
cART.
Our identification of plasma CXCL9 and CXCL10 as plasma
biomarkers associated with HIV infection is consistent with
previous studies [7,37,39,40,41], and increased CXCL10 and
IFNa were previously detected in HIV patients on cART
[7,19,37,41,42]. Elevated CXCL10 is also detected in other
chronic viral infections, including HCV [43,44,45], and HCV/
HIV coinfection [46,47,48], suggesting a role in the immune
response to viral infections. In the present study, we found
significant associations between plasma CXCL9 and CXCL10, in
addition to correlations of these chemokines with other inflam-
matory biomarkers including sIL-2R, IL-12, and CCL2. Consis-
tent with previous studies [37,38], CXCL10 correlated positively
with plasma VL, and inversely with CD4 T cell count, suggesting a
close relationship between CXCL10, HIV replication, and
markers of disease progression. A novel finding was the correlation
between CXCL10 and the frequency of CD16+ monocytes in
HIV patients on cART. A recent study found that the percentage
of CD14+CD16+ monocytes was significantly increased in PBMC
from melanoma patients exposed to IFNa ex vivo. This study also
found that increased CXCL10 induced by treatment with
recombinant IFNa was paralleled by expansion of CD14+/
CD16+ monocytes in vivo [49]. Another study reported increased
plasma CXCL10 in melanoma patients treated with relatively low
doses of IFNa associated with a trend towards increased frequency
of CD16+ monocytes in vivo [50]. Together, these findings suggest
that plasma CXCL10 is a biomarker closely associated not only
with HIV disease markers but also with an increased frequency of
CD16+ monocytes in vivo. The mechanism linking expansion of
CD16+ monocytes to increased CXCL10 levels remains unclear
and merits further investigation.
Because only plasma samples were available for the study, it was
not possible to address the cellular sources of elevated plasma
cytokines/chemokines. However, the biomarker pattern is indic-
ative of activated monocytes, plasmacytoid dendritic cells (pDC),
and myeloid dendritic cells (mDC), being likely sources. pDC are
the primary source of IFNa in HIV-infected individuals,
producing up to 1000-fold more than other cell types [10,51],
which in turn drives monocyte activation and monocyte
production of interferon-induced cytokines/chemokines including
CXCL9, CXCL10, and CCL2 [19]. CXCL9 and CXCL10,
produced mainly by activated monocytes/macrophages and
dendritic cells (both pDC and mDC), recruit CXCR3+ effector
and memory CD8 T cells and NK cells to sites of inflammation
[8,10,40,52]. IL-12 and CCL4 were elevated in viremic and
aviremic patients compared to controls, and IL-12 correlated with
IFNa, IFNc, CXCL9, and sIL-2R. These findings, together with
identification of the plasma biomarker signature consisting of
CXCL9, CXCL10, sIL-2R, and sCD14 and associations between
these biomarkers and elevated IL-12, produced mainly by mDC,
imply close relationships between persistent elevation of type I and
II interferons, IL-12, monocyte- and dendritic cell-derived
inflammatory cytokines/chemokines, and chronic activation of T
cells and monocytes in HIV patients on cART.
In the present study, plasma IL-12 was higher in aviremic than
in viremic HIV subjects. This finding is consistent with a recent
study [53] that showed an association between IFNa production
by pDC and IL-12 production by mDC in HIV patients with CD4
counts .200 cells/ml during cART therapy and higher DC
production of IL-12 at weeks 6 and 12 on cART in patients with
CD4 counts .200 cells/ml compared to those with CD4 counts
,200/ml. Consistent with previous studies [53,54], we found an
association between IL-12 and IFNa and -c in the study cohort of
HIV patients, and with CCL2, CCL4 in aviremic patients on
cART. In contrast, a recent study reported that untreated
progressive HIV infection was associated with increased CXCL10
and TNF, but decreased IL-12 and IL-15 [37], which may reflect
differences in the clinical characteristics of study subjects.
Unexpectedly, we found no significant difference in IFNa and
IFNc levels between HIV patients and controls, which may reflect
the wide range of IFN levels among healthy controls. Nonetheless,
the associations of IFNa, IFNc, CXCL9, and sIL-2R with IL-12,
together with previous studies demonstrating that IL-12 augments
IFNc responses, suggest that IL-12-mediated stimulation of IFNc
responses may be a factor contributing to T cell activation in HIV
patients on cART.
Consistent with prior studies, plasma sCD14 correlated not only
with IL-6 [18,55], but also with IL-15 [22,56]. Elevated IL-15 is
associated with higher plasma VL during acute HIV infection
[38], while IL-15 is expressed at higher levels in monocytes from
HIV-infected long-term nonprogressors compared to progressors
or uninfected controls [57]. IL-15 is a Th1 cytokine expressed on
monocytes upon activation that shares activities with IL-2, such as
stimulation of T cell proliferation and activation, but also
stimulates cell adhesion and production of proinflammatory
cytokines [58] and NK cell functions, including secretion of IFNc
and CCR5 ligands [59,60]. Excess IL-15 expression on monocytes
leads to increased MHC II expression, contributing to activation
or proliferation of T cells in diseases such as rheumatoid arthritis
[61]. In vitro priming of NK cells with IL-15 enhances secretion of
IFNc and CC chemokines in viremic and aviremic HIV patients
[54]. Thus, IL-15 has complex immunomodulatory effects that
can be beneficial, as well as pathogenic [61,62,63,64,65].
Crack cocaine use is associated with accelerated progression to
AIDS [66,67], but the mechanisms underlying this association are
unclear. Previous studies suggest that cocaine abuse may affect
HIV pathogenesis by causing an imbalance of Th1-Th2 cytokines
and stimulation of IFNc responses [68,69] and by upregulating
HIV coreceptors [70], possibly by acting through s-1 receptors
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tion of IFNc has been demonstrated in cocaine-dependent subjects
following intravenous cocaine infusion [69]. Our finding that a
cluster of viremic cocaine users had elevated sIL-2R, CXCL9,
CXCL10, CCL2, and CCL4 compared to other viremic subjects is
consistent with augmentation of interferon responses. Further-
more, PLS-DA and VIP scores identified upregulated sIL-2R and
downregulated IL-17 as top-ranked biomarkers accounting for
separation between viremic HIV subjects with versus without
active cocaine abuse. Downregulation of IL-17 could relate to
cocaine use via IFNc-mediated induction of indoleamine 2, 3-
dioxygenase (IDO) and tryptophan depletion in activated
monocytes/macrophages, a pathway previously linked to in-
creased immune activation in HIV-infected individuals abusing
cocaine and other stimulants [72,73]. IDO regulates the Th17/
Treg cell balance, with induction of IDO activity resulting in a
relative increase in Tregs and decrease in Th17 cells [74,75].
These findings raise the possibility that cocaine abuse may
augment T cell activation and promote Th17 cell depletion in
treated HIV patients via direct or indirect effects of cocaine on
IFNc-mediated pathways involving IDO and tryptophan metab-
olism.
We acknowledge several limitations to this study, including the
cross-sectional study design and small sample size, which may have
decreased the power to detect significant associations between
biomarker expression and disease markers or clinical subgroups.
Also, the narrow selection criteria used to define the study cohort
(CD4 nadir ,300) limit our findings to those with advanced HIV
disease and may also explain why biomarker levels were only
slightly higher in viremic than in aviremic HIV subjects. The study
cohort was from NNTC, which specifically recruits individuals
with advanced disease, and Lemuel Shattuck Hospital, which
treats a large population of HIV patients with advanced disease, to
represent a diverse population of HIV-infected individuals with
broad range of viral loads. Therefore, results cannot be
generalized to all populations. Indeed, the same cohort was used
to derive the plasma biomarker signature and examine its
classification accuracy for predicting HIV versus control subjects
(,80% accuracy). As such, we do not know if the classification
accuracy may be overestimated until the signature is examined in
additional cohorts. The multiplex bead assay provides a wealth of
expression data, but we are unable to conclude which cell types are
responsible for production of individual biomarkers. In view of
these limitations, future studies should utilize flow cytometric
assays along with multiplex assays and longitudinal cohorts
including subjects at earlier stages of disease to better define
relationships between the plasma biomarker signature identified in
the present study, chronic immune activation, and clinical
endpoints.
Conclusions
We identified a plasma inflammatory biomarker signature
consisting of 2 interferon stimulated gene products (CXCL9,
CXCL10), T cell activation marker (sIL-2R), and monocyte
activation marker (sCD14) that may be clinically useful as a
surrogate marker of immune activation in both viremic and
aviremic HIV patients on cART. Increased levels of the
interferon-induced chemokines CXCL9 and CXCL10 implicate
activation of IFN responses, while sIL-2R and sCD14 are markers
of T cell and monocyte activation, respectively. CXCL10
correlates with several disease markers including high plasma
VL, low CD4 counts, and expansion of the CD16+ monocyte
subset. Our analysis of IL-12 and other cytokine/chemokine
biomarkers implies a close relationship between persistent
elevation of type I and II interferons, IL-12, monocyte- and
dendritic cell-derived inflammatory cytokines/chemokines, and
activation of T cells and monocytes in HIV patients on cART.
Further studies are warranted to understand the clinical utility of
this combinatorial plasma inflammatory biomarker signature as a
surrogate marker to monitor immune activation and therapeutic
responses in HIV patients on cART with diverse clinical
phenotypes.
Supporting Information
Table S1 Plasma biomarker levels for all HIV subjects
and healthy controls, and clinical characteristics for
HIV subjects.
(XLS)
Figure S1 Unsupervised hierarchical clustering of plas-
ma CXCL9, CXCL10, sIL-2R, and sCD14 levels segre-
gates viremic and aviremic HIV subjects from controls
with ,80% accuracy. (A) Unsupervised hierarchical clustering
was performed by average linkage and Euclidean distance on 4
biomarkers (CXCL9, CXCL10, and sIL-2R and sCD14) across
viremic (A, blue boxes) and aviremic (B, orange boxes) HIV
subjects and healthy controls (black boxes). Analysis was run across
the covariates defining clinical group (A, viremic versus controls;
B, aviremic versus controls), plasma VL, and current and nadir
CD4 count. In heatmaps, red represents increased levels and blue
represents decreased levels relative to the mean levels of a
biomarker. Each column and row defines individual patients and
biomarkers, respectively. The analysis shows a low rate of
misclassification (7/35, corresponding to 20%, and 4/22,
corresponding to 18% for viremic and aviremic HIV subjects,
respectively) based on unsupervised hierarchical clustering.
(TIF)
Figure S2 Inflammatory biomarkers separate viremic
HIV subjects testing positive for cocaine from non-users
in PLS-DA. PLS-DA represented as three dimensional scatter
plot (left panel) shows the top 3 components of biomarker levels
measured in viremic HIV subjects with active cocaine use (with
positive urine toxicology) (red triangles, n=8) and non-users
(green triangles, n=8). Plot shows that 57.8% of the variance in
the matrix of biomarkers is explained by the first 3 components.
Variables important in projection (VIP) plot (right panel) ranks
sIL-2R and IL-17 as the top 2 biomarkers accounting for
separation between viremic HIV subjects with active cocaine use
and non-users.
(TIF)
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